Vertex Pharmaceuticals Buy Hold or Sell Recommendation

VRTX -- USA Stock  

Fiscal Quarter End: December 31, 2019  

Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding Vertex Pharmaceuticals Incorpor is 'Strong Hold'. Macroaxis provides Vertex Pharmaceuticals buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding VRTX positions. The advice algorithm takes into account all of Vertex Pharmaceuticals available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from VRTX buy-and-hold prospective. Also please take a look at Vertex Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool.

Time Horizon

Risk Tolerance

Symbol
Execute Advice
Sell Vertex PharmaceuticalsBuy Vertex Pharmaceuticals
Strong Hold

Volatility

Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

Inapplicable
For the selected time horizon Vertex Pharmaceuticals Incorpor has a risk adjusted performance of 0.1496, jensen alpha of 0.3572, total risk alpha of 0.1809, sortino ratio of 0.214 and treynor ratio of (1.63)
Macroaxis provides recommendation on Vertex Pharmaceuticals to complement and cross-verify current analyst consensus on Vertex Pharmaceuticals Incorpor. Our buy or sell recommendation engine determines the firm potential to grow exclusively from the prospective of investors current risk tolerance and investing horizon. To make sure Vertex Pharmaceuticals is not overpriced, please validate all Vertex Pharmaceuticals fundamentals including its Total Debt, Earnings Per Share and the relationship between Net Income and Book Value Per Share . Given that Vertex Pharmaceuticals has Number of Shares Shorted of 4 M, we advise you double-check Vertex Pharmaceuticals Incorpor market performance and probability of bankruptcy to make sure the company can sustain itself in the current economic cycle given your current risk tolerance and investing horizon.

Vertex Pharmaceuticals Trading Alerts and Improvement Suggestions

Over 97.0% of the company outstanding shares are owned by institutional investors
Latest headline from MacroaxisInsider: Sale by Joshua Boger of 2100 shares of Vertex Pharmaceuticals

Vertex Pharmaceuticals current analysts recommendations

Target Median Price230.50
Target Mean Price232.27
Recommendation Mean1.90
Target High Price285.00
Number Of Analyst Opinions22
Target Low Price200.00

Vertex Pharmaceuticals Returns Distribution Density

Mean Return0.35Value At Risk1.91
Potential Upside2.79Standard Deviation1.50
 Return Density 
      Distribution 

Vertex Pharmaceuticals Greeks

α
Alpha over DOW
=0.36
β
Beta against DOW=0.21
σ
Overall volatility
=1.51
Ir
Information ratio =0.18

Vertex Pharmaceuticals Volatility Alert

Vertex Pharmaceuticals Incorpor has relatively low volatility with skewness of 0.17 and kurtosis of 0.19. However, we advise all investors to independently investigate Vertex Pharmaceuticals Incorpor to ensure market all accessible information is consistent with the expectations about its upside potential and future risk-adjusted return.
    
 Better Than Average     
    
 Worse Than Average Compare Vertex Pharmaceuticals to competition

Vertex Pharmaceuticals Fundamental Vs Peers

FundamentalsVertex PharmaceuticalsPeer Average
Return On Equity51.75 (0.31) 
Return On Asset8.30 (0.14) 
Profit Margin59.24 (1.27) 
Operating Margin25.01 (5.51) 
Current Valuation53.43 B16.62 B
Shares Outstanding257.15 M571.82 M
Shares Owned by Insiders0.26 10.09 
Shares Owned by Institutions96.96 39.21 
Number of Shares Shorted4 M4.71 M
Price to Earning26.83 28.72 
Price to Book10.83 9.51 
Price to Sales15.71 11.42 
Revenue3.62 B9.43 B
Gross Profit1.22 B27.38 B
EBITDA905.3 M3.9 B
Net Income2.14 B570.98 M
Cash and Equivalents4 B2.7 B
Cash per Share15.54 5.01 
Total Debt649.8 M5.32 B
Debt to Equity12.30 48.70 
Current Ratio3.44 2.16 
Book Value Per Share20.42 1.93 K
Cash Flow from Operations1.07 B971.22 M
Short Ratio2.73 4.00 
Earnings Per Share8.24 3.12 
Price to Earnings To Growth1.55 4.89 
Number of Employees2.5 K18.84 K
Beta1.46-0.15
Market Capitalization56.86 B19.03 B
Total Asset2.5 B29.47 B
Retained Earnings(4.71 B)9.33 B
Working Capital900.8 M1.48 B
Current Asset1.41 B9.34 B
   Vertex Pharmaceuticals exotic insider transaction detected [view details]

Vertex Pharmaceuticals Market Momentum

Search macroaxis.com